Placeholder

Bio Meets Pharma to Form the New Age of Biopharma

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

The pharmaceutical and biotech industries are gradually integrating into one biopharmaceutical industry. In a white paper released in May 2005 by the Life Sciences and Health Care practices of Deloitte, it was surmised that the distinction between biotechnology and pharmaceutical firms will erode over the next decade.
Strictly speaking, the term “pharmaceutical” refers to medicines composed of small, synthetically produced molecules. “Biotechnology” products are typically large molecules developed through cellular and biomolecular technologies that capitalize on the attributes of cells, DNA, and proteins. Some say the pharmaceutical industry’s pipeline hinges on the R&D efforts of biotech companies. Large pharma companies are seeking more alliances with biotech through acquisition or licensing agreements, with such alliances rising to 502 in 2004 from 69 in 1993, according to a Deloitte Consulting study, Critical Factors for Alliance Formation…

Sidebars:
Industry Trends
Growth in Global Biotechnology 2004-2005

Experts on this Topic
Ben Bonifant. Leader, Business Development Practice, Campbell Alliance, Raleigh, N.C.; Campbell Alliance is a management consulting firm specializing in the pharmaceutical and biotech industries. For more information, visit campbellalliance.com.
Helene Ellison. President and CEO, HealthStar Public Relations LLC, New York; HealthStar Public Relations is a marketing services company offering a comprehensive portfolio of traditional and unique services. For more information, visit healthstarcom.com.
William J. Kridel Jr., J.D. Founder and Managing Director, Ferghana Partners Group, New York; Ferghana is a provider of high-level, independent corporate finance advice to firms in the biotechnology, pharmaceuticals, diagnostics, and specialty chemical industries. For more information, visit ferghanapartners.com.
Louise Makin. CEO, BTG Plc., London; BTG acquires rights to early-stage pharmaceuticals and other medical technologies from a global network of pharmaceutical and biotech companies and research institutions. For more information, visit btgplc.com.
Glenn Snyder. Principal with the Life Sciences & Health Care Practice, Deloitte Consulting LLP, San Francisco; Deloitte delivers services in four professional areas: audit, tax, consulting, and financial advisory. For more information, visit deloitte.com.
Bob Stein, M.D., Ph.D. President, Roche Palo Alto LLC, Palo Alto, Calif.; Roche, a member of the Roche Group, is one of the world’s leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more information, visit rocheusa.com.
John Watson. VP, Corporate Marketing and Sales, Covance Inc., Princeton, N.J.; Covance is a comprehensive drug-development services company with a portfolio of services from preclinical development through drug commercialization. For more information, visit covance.com.

FEEDBACK